Status:
COMPLETED
To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.
Eligibility Criteria
Inclusion
- Healthy male volunteers.
- Clinically normal physical findings (incl. Electrocardiogram (ECG)) and laboratory values as judged by the investigator.
- Have a body mass index (BMI) ≥19 and ≤30
Exclusion
- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
- Intake of any prescribed medicine and OTC drugs (including herbals, vitamins and minerals), except for occasional paracetamol or nasal spray for nasal congestion, within two weeks before the first administration of the investigational product.
- Daily use of nicotine containing substances.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00790153
Start Date
November 1 2008
End Date
February 1 2009
Last Update
April 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chula Vista, California, United States